Astragalus Polysaccharide Improves Myocardial Fibrosis in Hypertrophic Cardiomyopathy Through the TGF-β1/Smad3 Signal Pathway
Frontiers in Bioscience-Landmark · 2025
DOI: 10.31083/fbl45595 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2025. Verfasst von Nana Qin und 2 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, 11001…. Hauptthemen laut MEDLINE: Smad3 Protein, Transforming Growth Factor beta1, Polysaccharides, Signal Transduction. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Myocardial fibrosis is a key pathological driver of Hypertrophic Cardiomyopathy (HCM), contributing to adverse remodeling and poor prognosis. The transforming growth factor-β1/Smad3 (TGF-β1/Smad3) signaling cascade plays a central role in fibrogenesis; however, effective antifibrotic therapies remain limited. Astragalus polysaccharide (APS), a bioactive constituent of Astragalus membranaceus, has demonstrated cardioprotective potential. Nevertheless, the mechanisms underlying its effects in HCM-associated fibrosis remain unknown.
Methods
Pressure overload induced HCM was established in C57BL/6J mice using transverse aortic constriction (TAC), and animals were randomized to control, TAC, low-dose APS (50 mg/kg/day), or high-dose APS (100 mg/kg/day) groups. Cardiac function was evaluated by echocardiography, while myocardial hypertrophy and fibrosis were assessed by morphometry, Masson’s staining, and collagen I (Col-I) expression analysis. Parallel in vitro studies employed angiotensin II stimulated (Ang II-stimulated) H9C2 cardiomyocytes, with or without the TGF-β1/Smad3 agonist SRI-011381, to explore mechanistic pathways.
Results
TAC induced marked cardiac dysfunction, ventricular dilation, and extensive fibrosis, accompanied by upregulation of TGF-β1, phosphorylated Smad3, and Col-I expression (all p < 0.05). APS treatment dose-dependently preserved systolic function, attenuated collagen deposition, and suppressed activation of the TGF-β1/Smad3 axis, with the strongest effects observed in the high-dose group. In vitro, APS significantly inhibited Ang II induced hypertrophy and fibrotic protein expression; these effects were abrogated by SRI-011381, confirming pathway specificity.
Conclusions
APS exerts cardioprotective and antifibrotic effects in HCM by inhibiting the TGF-β1/Smad3 signaling pathway. These findings highlight APS as a promising therapeutic candidate for targeting myocardial fibrosis and improving outcomes in HCM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, 110016 Shenyang, Liaoning, China.
- Graduate School of Changchun University of Chinese Medicine, 130117 Jilin, Jilin, China.
Zitieren
APA
Qin, N., Wu, W., & Li, B. (2025). Astragalus Polysaccharide Improves Myocardial Fibrosis in Hypertrophic Cardiomyopathy Through the TGF-β1/Smad3 Signal Pathway. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl45595
Vancouver
Qin N, Wu W, Li B. Astragalus Polysaccharide Improves Myocardial Fibrosis in Hypertrophic Cardiomyopathy Through the TGF-β1/Smad3 Signal Pathway. Frontiers in Bioscience-Landmark. 2025. doi:10.31083/fbl45595
BibTeX
@article{Qin2025,
author = {Qin, Nana and Wu, Wenjun and Li, Baoyin},
title = {Astragalus Polysaccharide Improves Myocardial Fibrosis in Hypertrophic Cardiomyopathy Through the TGF-β1/Smad3 Signal Pathway},
journal = {Frontiers in Bioscience-Landmark},
year = {2025},
doi = {10.31083/fbl45595}
}
EUVIMED